Entering text into the input field will update the search result below

Inovio Pharmaceuticals, Inc. (INO) Oppenheimer 33rd Annual Healthcare Conference (Transcript)

Mar. 13, 2023 3:03 PM ETInovio Pharmaceuticals, Inc. (INO)
SA Transcripts profile picture
SA Transcripts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Oppenheimer 33rd Annual Healthcare Conference Call March 13, 2023 10:40 AM ET

Company Participants

Jacqueline Shea - President and Chief Executive Officer

Conference Call Participants

Hartaj Singh - Oppenheimer

Hartaj Singh

Great, thank you. Thanks always to the operators for making this so easy. Hey, everybody. I apologize for the little delay here. I just had a lack of a better term a brain fart. And we have Jacqueline Shea here with us with Inovio, representing the company and giving us an update. We listened to the company’s fourth quarter call recently, caught up with the company afterwards. So, really looking forward to getting a quick update from Jacque. Jacque, maybe the best way to start would be if you could kind of give us a State of the Union, where Inovio is at for about 3 to 5 minutes and then we can jump into the fireside chat.

Jacqueline Shea

That sounds great, Hartaj and thanks for the invite this morning. It’s nice to see you again. So, Inovio is a company that’s developing DNA medicines. And we do this by designing precisely designed DNA plasmids and then we deliver them with our smart device called CELLECTRA. And we are developing DNA medicines against cancers, HPV-related diseases and also some infectious diseases. So, we have some pipeline candidates that we have recently reported data across our HPV-related diseases, so for VGX-3100 against cervical dysplasia or HSIL for INO-3107, which is our product candidate against recurrent respiratory papillomatosis, or RRP.

Then on our immunooncology side, we have a candidate called INO-5401, against glioblastoma that we have been evaluating in glioblastoma in combination with Regeneron’s PD-1 inhibitor, Libtayo. And we also have a candidate called INO-3112, which was previously licensed out to AstraZeneca was returned to us last year. And we have been

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.